Tuberculosis and atypical mycobacterial infections in ruxolitinib treated patients with primary or secondary myelofibrosis or polycythemia vera.

Fiche publication

Date publication

janvier 2019

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HERBRECHT Raoul , Pr MAUVIEUX Laurent , Dr AME Shanti , Pr FORNECKER Luc-Matthieu

Tous les auteurs :
Lescuyer S, Ledoux MP, Gravier S, Natarajan-Amé S, Duval C, Maloisel F, Mauvieux L, Toussaint E, Fornecker LM, Herbrecht R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30639623

Résumé

Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated in the treatment of polycythemia vera and primary or secondary myelofibrosis. Only one (0.2%) patient was diagnosed with tuberculosis among the 485 patients receiving ruxolitinib in the four pivotal trials. Fourteen cases of tuberculosis have since been reported. We observed two (3%) mycobacterial infections (one due to Mycobacterium tuberculosis and one due to Mycobacterium avium complex) in our cohort of 65 patients receiving ruxolitinib. Our observation suggests that the rate of mycobacterial infection might be higher than that observed in the pivotal trials and that atypical mycobacterial infections can also occur.